Product Description
PanKRAS inhibitor 2G for lung and GI cancers in preclinical development. (Sourced from: https://www.beigene.com/science/pipeline/)
Mechanisms of Action: KRAS Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BeiGene
Company Location:
Company CEO: John V. Oyler
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Korea, New Zealand, South Korea, Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06585488 |
BGB-53038-101 | P1 |
Recruiting |
Gastrointestinal Cancer|Pancreatic Ductal Carcinoma|Pancreatic Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer|Colorectal Cancer|Esophageal Cancer|Squamous Cell Carcinoma |
2026-12-01 |
12% |
2025-07-11 |
|
CTR20250063 |
CTR20250063 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-10-05 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/27/2025 |
News Article |
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
|
11/12/2024 |
News Article |
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates |